Zhengye Biotechnology Holding Limited (ZYBT) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Zhengye Biotechnology Holding Limited (ZYBT)

View Full Profile →

Intrinsic Value

DCF Not Suitable for ZYBT

Market cap ($0.05B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.

Alternative Approach:

Use relative valuation (P/E, P/S) vs. peer group.

Frequently Asked Questions

Is ZYBT stock undervalued or overvalued?

Insufficient data to compute DCF valuation for ZYBT. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is ZYBT's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is ZYBT's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For ZYBT, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.